European Commission Approves IMBRUVICA in Two Forms of Blood Cancer, First-in-class BTK inhibitor for complex orphan diseases CLL and MCL
- EMEA Innovative Medicine
- European Commission Approves IMBRUVICA for Blood Cancer Treatments
European Commission Approves IMBRUVICA for Blood Cancer Treatments
- X (Twitter)
Copy link